Janus Henderson Global Life Sciences D JNGLX

Medalist Rating as of | See Janus Henderson Investment Hub
  • NAV / 1-Day Return 80.23  /  −0.48 %
  • Total Assets 5.9 Bil
  • Adj. Expense Ratio
    0.800%
  • Expense Ratio 0.800%
  • Distribution Fee Level Below Average
  • Share Class Type No Load
  • Category Health
  • Investment Style Large Growth
  • Min. Initial Investment 2,500
  • Status Limited
  • TTM Yield 0.11%
  • Turnover 34%

USD | NAV as of Sep 25, 2024 | 1-Day Return as of Sep 25, 2024, 10:34 PM GMT+0

Morningstar’s Analysis JNGLX

Will JNGLX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Janus Henderson Global Life Sciences D’s Process Pillar rating is Average, but a strong management team still helps this strategy retain its Morningstar Medalist Rating of Bronze.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The strategy charges fees in line with its similarly distributed peers, priced within the middle quintile.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings JNGLX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 41.8
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

8.12 458.5 Mil
Healthcare

UnitedHealth Group Inc

6.90 389.9 Mil
Healthcare

Novo Nordisk AS Class B

5.45 308.1 Mil
Healthcare

AbbVie Inc

3.87 218.7 Mil
Healthcare

AstraZeneca PLC

3.84 216.8 Mil
Healthcare

Amgen Inc

3.29 186.0 Mil
Healthcare

Merck & Co Inc

2.95 166.7 Mil
Healthcare

Sanofi SA

2.55 144.3 Mil
Healthcare

Vertex Pharmaceuticals Inc

2.44 137.8 Mil
Healthcare

Boston Scientific Corp

2.34 132.4 Mil
Healthcare

Sponsor Center